TBI with Long Bone Protection (GI-ARS)

Description

Exposure to high levels of ionizing radiation results in toxicities of the gastrointestinal (GI) tract that often lead to death. There is a critical need to develop therapies that treat the damaged GI tract to reduce or prevent exposure-related deaths. At BioModels, evaluate your test compounds for efficacy in targeting the GI tract in our validated GI-directed acute radiation syndrome mouse model. In this model, one hind limb of an anesthetized animal is protected using a lead shield while a single, precise dose of total body irradiation (x-ray) is delivered. The main endpoints of the model include survival and body weight change. Histological endpoints can also be examined to address the mechanism of action.

  • Advantages: Good for screening potential drug candidates, consistent disease incidence
  • Disadvantages: Survival as a primary endpoint minimizes sample collection, two radiation doses are highly recommended
Model Systems
  • C57Bl/6 Mice
Standard Readouts
  • Survival
  • Percent weight change
  • Blood Cell Count (CBC)
  • Terminal small intestine histopathology and/or IHC analyses
Additional Readouts
  • Systemic Cytokine Analysis
  • Gene expression
  • Custom assays
Representative DataClick Image to Enlarge
Percent Body Weight Change in Animals Receiving TBI With Long Bone Protection

C57Bl/6 animals that receive TBI with long bone protection are weighed daily, and body weight change as compared to Day 0 are calculated and shown over the course of the study for each radiation (x-ray) dose level.

Survival in Animals Receiving TBI With Long Bone Protection

Survival of C57Bl/6 mice that receive TBI (x-ray) with long bone protection is tracked daily over the course of the study.

Small Intestine Histopathology in Animals Receiving TBI With Long Bone Protection

C57Bl/6 mice receive TBI (x-ray) with long bone protection. Representative images show the epithelial architecture of the villi and crypts of normal jejunum (A) and damaged jejunum (B) 4 days after exposure to radiation.

Daniel Lichtman

Managing Partner